DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Rebastinib is an investigational drug.
There have been 4 clinical trials for Rebastinib. The most recent clinical trial was a Phase 1 trial, which was initiated on September 26th 2018.
The most common disease conditions in clinical trials are Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, and Carcinoma. The leading clinical trial sponsors are Deciphera Pharmaceuticals LLC, Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center.
There are one hundred and sixty-eight US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Rebastinib
|A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors||Deciphera Pharmaceuticals LLC||Phase 1/Phase 2|
|A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors||Deciphera Pharmaceuticals LLC||Phase 1/Phase 2|
|Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer||Albert Einstein College of Medicine of Yeshiva University||Phase 1|
Top disease conditions for Rebastinib
Top clinical trial sponsors for Rebastinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Rebastinib||Get Started Free||ALK and NTRK1 fusion molecules and uses thereof||FOUNDATION MEDICINE, INC. (Cambridge, MA)||Get Started Free|
|Rebastinib||Get Started Free||Use of inhibitors of Bruton'S tyrosine kinase (Btk)||Pharmacyclics LLC (Sunnyvale, CA)||Get Started Free|
|Rebastinib||Get Started Free||Use of inhibitors of Bruton's tyrosine kinase (Btk)||Pharmacyclics LLC (Sunnyvale, CA)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Rebastinib||World Intellectual Property Organization (WIPO)||WO2013059740||2031-10-21||Get Started Free|
|Rebastinib||Australia||AU2011261185||2030-06-03||Get Started Free|
|Rebastinib||Australia||AU2015275321||2030-06-03||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|